Authors

Latest:

Primary Results from the Phase 3 Leap-002 Study: Lenvatinib plus Pembrolizumab versus Lenvatinib as First-Line Therapy for Advanced Hepatocellular Carcinoma

Dr Finn reviews the results from the Leap-002 study which evaluates the use of lenvatinib with pembrolizumab in the front-line setting for patients with advanced hepatocellular carcinoma.

Richard S. Finn, MD, Geffen School of Medicine

Latest:

Hepatocellular Carcinoma: A Rapidly Evolving Treatment Landscape

Discussion around topics pertaining to the use of systemic therapy in advanced liver cancer. Topics will include the latest research in the field and the impact of recent clinical trials on making decisions around treatment selection.

Richard S. Finn, MD, Geffen School of Medicine at UCLA

Richard S. Finn, MD, UCLA Health

Latest:

Challenges of Sequencing and Biomarkers in HCC

Experts provide insight into the challenges of sequencing and biomarkers when treating advanced HCC.

Richard S. Finn, MD, University of California Los Angeles

Richard S. Pelman, MD

Latest:

Dr. Pelman on Determining Treatments for Newly Diagnosed Prostate Cancer

Richard S. Pelman, MD, president of the American Association of Clinical Urologists and an urologist at the University of Washington Department of Urology, discusses techniques for selecting patients for radical prostatectomy or watchful waiting and active surveillance.

Richard Stock, MD

Latest:

Dr. Richard Stock on Brachytherapy for Prostate Cancer

Richard Stock, MD, a professor of radiation oncology at the Icahn School of Medicine at Mount Sinai Hospital, talks about brachytherapy and its benefits for patients with prostate cancer.

Richard T. Maziarz, MD

Latest:

Use of CAR T-Cell Therapies in Earlier Lines of DLBCL

Panelists discuss data on the use of CAR T-cell therapies in earlier lines and implications of these data on the DLBCL treatment landscape going forward.

Richard T. Penson, MD

Latest:

Dr. Penson on Olaparib Monotherapy Vs Chemo in Ovarian Cancer

Richard T. Penson, MD, MRCP, associate professor, Harvard Medical School, and clinical director, Medical Gynecologic Oncology, Massachusetts General Hospital, compares olaparib (Lynparza) monotherapy with chemotherapy for patients with relapsed germline BRCA-mutated (gBRCAm) platinum-sensitive ovarian cancer.

Richard T. Penson, MD, MRCP

Latest:

Dr. Penson on PARP Inhibitors as Switch Maintenance Therapy in Recurrent Ovarian Cancer

Richard T. Penson, MD, MRCP, discusses selecting between PARP inhibitors for switch maintenance therapy in recurrent ovarian cancer.

Richard T. Silver, MD

Latest:

Dr. Richard Silver Discusses the High Cost of Drugs in CML

Richard T. Silver, MD, from the New York Presbyterian-Weill Cornell Medical Center, comments on the cost of drugs to treat chronic myeloid leukemia.

Richard W. Joseph, MD

Latest:

Dr. Joseph on Molecular Signatures in mRCC

Richard W. Joseph, MD, internist and oncologist, Mayo Clinic, discusses molecular signatures in metastatic renal cell carcinoma (mRCC).

Richard W. Joseph, MD, Mayo Clinic

Richard Wong, MD

Latest:

Novel Approach Reduces Treatment Toxicities in Patients With HPV-Related Oropharyngeal Cancer

The incidence of mouth and throat cancer is on the rise due to transmission of the human papilloma virus, but physicians at Memorial Sloan Kettering Cancer Center have managed to significantly reduce the intensity of treatment and improve quality of life for these patients.

Rickey C. Miller, PharmaD, BCPS, BCOP

Latest:

Challenges in Treating Chemotherapy-Induced Anemia

Practicing clinicians and healthcare administrators face many challenges in treating cancer patients, including management of chemotherapy-induced anemia.

Rimas V. Lukas, MD

Latest:

Dr Lukas on Survival Outcomes With Eflornithine in IDH-Mutant Anaplastic Astrocytoma

Rimas V. Lukas, MD, discusses the efficacy of eflornithine plus lomustine in recurrent IDH-mutant anaplastic astrocytoma per 2021 WHO diagnostic criteria.

Rita Colorito

Latest:

Early Findings Support Novel Regimen for Unresectable HCC

Atezolizumab (Tecentriq) plus bevacizumab (Avastin) resulted in clinically meaningful and durable objective responses as first-line therapy for patients with previously untreated, unresectable disease.

Rita Nanda

Latest:

Dr Nanda on Treatment De-Escalation in HER2+ Breast Cancer and TNBC

Rita Nanda, MD, discusses efforts to de-escalate adjuvant therapy for patients with select breast cancers who responded to neoadjuvant therapy.

Rita Nanda, MD, The University of Chicago Medicine

Latest:

Dr Nanda on Neoadjuvant Treatment in HER2+ Breast Cancer

Rita Nanda, MD, discusses the future of neoadjuvant treatment for patients with HER2-positive breast cancer.

Ritu Salani, MD

Latest:

Dr Salani on Managing Mirvetuximab Soravtansine–Associated Ocular Toxicities in Ovarian Cancer

Ritu Salani, MD, MBA, discusses the management of ocular toxicities associated with mirvetuximab soravtansine in ovarian cancer.